Literature DB >> 1722417

Immunodetection of the ligand-activated receptor for epidermal growth factor.

R Campos-González1, J R Glenney.   

Abstract

Many receptors for cellular growth factors are known to be protein tyrosine kinases which become activated upon ligand binding at their extracellular domain. We describe here a method to detect the activation state of Epidermal Growth Factor receptor (EGFr) with a monoclonal antibody (mAb74). This antibody was found to preferentially recognize the ligand-activated EGFr as detected by immunoprecipitation, Western blotting and immunocytochemical techniques. mAb74 did not recognize other tyrosine-phosphorylated proteins and was not inhibited by phosphotyrosine, suggesting that it is recognizing an epitope specific for the ligand-activated EGF receptor. The reactivity of mAb74 towards EGFr was closely correlated with the EGF-dependent tyrosine phosphorylation of endogenous substrates. This antibody allows one to detect the activated EGF receptor in vitro or in vivo even in a complex mixture of other tyrosine kinases and substrates.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722417     DOI: 10.3109/08977199109043916

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  7 in total

1.  Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.

Authors:  R J Epstein; B J Druker; T M Roberts; C D Stiles
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

Review 2.  The ErbB receptors as targets for breast cancer therapy.

Authors:  J Albanell; J Baselga
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

3.  Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.

Authors:  X Ouyang; T Gulliford; H Zhang; G Smith; G Huang; R J Epstein
Journal:  Mol Cell Biochem       Date:  2001-02       Impact factor: 3.396

4.  Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail.

Authors:  A Bishayee; L Beguinot; S Bishayee
Journal:  Mol Biol Cell       Date:  1999-03       Impact factor: 4.138

5.  A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  G Goss; H Hirte; W H Miller; I A J Lorimer; D Stewart; G Batist; D A E Parolin; P Hanna; S Stafford; J Friedmann; W Walsh; S Mathews; L Douglas; L K Seymour
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

6.  Inhibition of COX-2 with NS-398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapy.

Authors:  N Banu; A Buda; S Chell; D Elder; M Moorghen; C Paraskeva; D Qualtrough; M Pignatelli
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

Review 7.  A Brief History of Single-Particle Tracking of the Epidermal Growth Factor Receptor.

Authors:  David T Clarke; Marisa L Martin-Fernandez
Journal:  Methods Protoc       Date:  2019-01-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.